Alnylam Pharmaceuticals Inc (ALNY)

107.43 -1.42  -1.30% NASDAQ Apr 1, 13:21 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/06/2020 12:00 EDT Misc Alnylam Pharmaceuticals Inc Annual General Meeting for 2019
05/01/2020 20:30 EDT Misc Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call in 2020
05/01/2020 Earnings Alnylam Pharmaceuticals Inc First Quarter Earnings in 2020 Release
02/13/2020 Misc Alnylam Pharmaceuticals Inc Annual Report for 2019
02/06/2020 08:30 EST Misc Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2019
02/06/2020 Earnings Alnylam Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release
10/31/2019 08:30 EDT Misc Alnylam Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019
10/31/2019 Earnings Alnylam Pharmaceuticals Inc Third Quarter Earnings in 2019 Release
08/06/2019 08:00 EDT Misc Alnylam Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019
08/06/2019 Earnings Alnylam Pharmaceuticals Inc Second Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.alnylam.com
  • Investor Relations URL: http://investors.alnylam.com/index.cfm
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: May. 01, 2020
  • Last Earnings Release: Feb. 06, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria (AHP), Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.51%
FXH First Trust Health Care AlphaDEX® ETF 2.39%
VGHCX Vanguard Health Care Inv 2.22%
FBIOX Fidelity® Select Biotechnology 2.17%
XBI SPDR® S&P Biotech ETF 1.93%
IBB iShares Nasdaq Biotechnology ETF 1.63%
FCGSX Fidelity® Series Growth Company 1.36%
FGCKX Fidelity® Growth Company K 1.33%
FSPHX Fidelity® Select Health Care 1.03%
SCHM Schwab US Mid-Cap ETF™ 0.50%
VEXMX Vanguard Extended Market Index Investor 0.27%
VXF Vanguard Extended Market ETF 0.27%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.